ALZHEIMER S

Brand Owner (click to sort) Address Description
A WORLD WITHOUT ALZHEIMER'S ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION, INC. 225 N. Michigan Avenue Chicago IL 60601 A WORLD WITHOUT ALZHEIMERS;ALZHEIMER'S;Medical Research;
ALZ.ORG ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION, INC. 225 N. Michigan Avenue Chicago IL 60601 ALZHEIMER'S;Clothing, namely, t-shirts;Charitable fundraising services;Association services, namely, promoting the interests of those with neurodegenerative disorders before the general public, political entities, legislative bodies and health care and long term care providers; promoting the interests of those concerned with the prevention, detection, treatment and elimination of neurodegenerative disorders; promoting public awareness of neurodegenerative disorders;Providing support groups, namely, organizing and conducting support groups in the field of neurodegenerative disorders; online social networking services provided through community website;Providing medical information;Medical research;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the ?-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the A? region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, ?-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.